Dexcom (Nadsaq:DXCM) today announced new insulin delivery integrations and updates on enhanced continuous glucose monitors ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" or "the Company")  for violations of §§10(b) and 20(a) ...

Burke Wealth Management, an investment management company, released its “Focused Growth Strategy” fourth quarter 2024 ...

Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options ...

Polen Capital, an investment management company, released its “Polen Global Growth Strategy” fourth-quarter 2024 investor ...

In this video, I will cover the recent updates regarding Novo Nordisk (NYSE: NVO). Watch the short video to learn more, ...

Novo Nordisk (NYSE: NVO), the Danish company best known as the maker of weight loss drug Wegovy, expanded a little on the ...

The consensus price target hints at a 44.2% upside potential for Novo Nordisk (NVO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.

Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects ...